Russell Investments Group
VTGN icon

Russell Investments Group’s VistaGen Therapeutics VTGN Stock Holding History

Russell Investments Group’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-30
Closed -$56 – 3634
2023
Q2 		$56 Hold
30
– – ﹤0.01% 3438
2023
Q1 		$112 Buy
+30
New +$157 ﹤0.01% 3273
2022
Q2 		– Sell
-277
Closed -$10K – 2974
2022
Q1 		$10K Hold
277
– – ﹤0.01% 2710
2021
Q4 		$16K Hold
277
– – ﹤0.01% 2963
2021
Q3 		$22K Buy
+277
New +$24.1K ﹤0.01% 2995

Other funds holding VTGN

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group's VTGN Position: Q3 2023 in Review

Russell Investments Group sold out of VistaGen Therapeutics (VTGN) in Q3 2023, closing a stake of 30 shares — an estimated $56 sold.

Russell Investments Group first reported a position in VTGN in Q3 2021 and held it in 5 quarters. The position peaked at $22K in Q3 2021. 34 funds tracked by Wall St. Rank hold VTGN as of Q3 2023.

  • Russell Investments Group reported no remaining VistaGen Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Russell Investments Group sold 30 VistaGen Therapeutics shares in Q3 2023, an estimated $56.
  • Russell Investments Group first reported a position in VistaGen Therapeutics in Q3 2021 and held it in 5 quarters.
  • Russell Investments Group's VistaGen Therapeutics position peaked at $22K in Q3 2021.
  • 34 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2023.

Based on Russell Investments Group's 13F filing for Q3 2023, filed 13 Nov 2023.